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bjectives We sought to assess changes in antirestenotic efﬁcacy of drug-eluting stents (DES) by
estudying subjects at 2 time points after coronary stenting (6 to 8 months and 2 years) and to
ompare differences in time courses of late luminal loss (LLL) between 3 different DES platforms in
se at our institution.
ackground DES therapy is associated with low levels of LLL at 6 to 8 months. The temporal
ourse of neointimal formation after this time point remains unclear.
ethods This prospective, observational, systematic angiographic follow-up study was conducted
t 2 centers in Munich, Germany. Patients underwent stenting with permanent-polymer rapamycin-
luting stents (RES), polymer-free RES, or permanent-polymer paclitaxel-eluting stents (PES). The pri-
ary end point was delayed LLL (the difference in in-stent LLL between 6 to 8 months and 2 years).
esults Of 2,588 patients undergoing stenting, 2,030 patients (78.4%) had 6- to 8-month angio-
raphic follow-up and were enrolled in the study. Target lesion revascularization was performed in
59 patients; these patients were not considered for further angiographic analysis. Of 1,771 remain-
ng patients, 1,331 had available 2-year reangiographic data (75.2%). Overall mean (SD) delayed LLL
as 0.12  0.49 mm (0.17  0.50 mm, 0.01  0.42 mm, and 0.13  0.50 mm in permanent-polymer
ES, polymer-free RES, and permanent-polymer PES groups, respectively [p  0.001]). In multivariate
nalysis, only stent type (in favor of polymer-free RES) predicted delayed LLL.
onclusions Ongoing erosion of luminal caliber beyond 6 to 8 months after the index procedure is
bserved following DES implantation. Absence of permanent polymer from the DES platform seems
o militate against this effect. (J Am Coll Cardiol Intv 2009;2:291–99) © 2009 by the American
ollege of Cardiology Foundation
rom the *Deutsches Herzzentrum and †1. Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany.
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292radual erosion of acute procedural luminal gains has long
een the Achilles’ heel of percutaneous coronary interven-
ion (1). Although the evolution of elective coronary stent
lacement largely negated the impact of plaque prolapse,
essel recoil, and constrictive remodeling on coronary reste-
osis, an iatrogenic condition—neointimal hyperplasia—
ssumed the role of chief culprit in delayed loss of antirest-
notic efficacy. The evolution of drug-eluting stents (DES),
hich initially appeared to have the potential to virtually
liminate this process at 6 to 8 months after intervention,
as represented a very significant milestone in percutaneous
oronary intervention. Widespread adoption of DES ther-
py has been accompanied by a surfeit of angiographic
ollow-up data showing well-preserved luminal gain over 6
o 8 months, even in subsets of patients with complex lesion
orphology (2–4).
See page 300
Since inception, however, some misgivings have re-
mained regarding the durability
of efficacy, and the dynamics of
changes in luminal caliber be-
yond 6 to 8 months after inter-
vention remain largely unstud-
ied. Animal model investigation
reported evidence of “catch-up
restenosis” at time points beyond
those seen in bare-metal stent
(BMS) animal studies (5–7).
Occasional clinical reports also
documented experiences with
delayed loss of antirestenotic ef-
ficacy (8–10). Although sequen-
ial follow-up angiographic studies described the temporal
ourse of and peak in coronary restenosis during both the
ra of conventional balloon angioplasty (11,12) and BMS
mplantation (13–15), such an analysis remains a scientific
ap in the age of DES therapy.
Against this background, the current study was designed
o assess longitudinal changes in the antirestenotic efficacy
f DES in a real-world setting by restudying subjects at 2
ime points following coronary stenting, namely 6 to 8
onths and 2 years. In addition, we sought to assess the
elative changes in antirestenotic efficacy of 3 different stent
latforms—permanent-polymer rapamycin-eluting stents
RES) (Cypher, Cordis Corporation, Miami Lakes, Flor-
da), polymer-free RES (developed in the setting of the
SAR [Intracoronary Stent and Antithrombotic Research]
roject), and permanent-polymer paclitaxel-eluting stents
PES) (Taxus, Boston Scientific, Natick, Massachu-
etts)—in clinical use at our institution over the same
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
LL  late luminal loss
ES  paclitaxel-eluting
tent(s)
ES  rapamycin-eluting
tent(s)
LR  target lesion
evascularizationeriod. cethods
tudy population and procedural details. This prospective,
bservational study included patients older than 18 years
ho were undergoing DES implantation at 2 German
enters in Munich, Germany, between January 2003 and
uly 2006, due to ischemic symptoms or evidence of myo-
ardial ischemia in the presence of 50% de novo stenosis
ocated in native coronary vessels. Patients with a target
esion located in the left main stem or in a bypass graft, with
n-stent restenosis or acute myocardial infarction, or with
alignancies or other comorbid conditions (e.g., severe
iver, renal, and pancreatic disease) with life expectancy less
han 24 months or that may result in protocol noncompli-
nce were considered ineligible for the study. The study
rotocol was approved by the institutional ethics committee
esponsible for both participating centers, the Deutsches
erzzentrum München and the Medizinische Klinik I,
linikum rechts der Isar, Munich, Germany. All patients
ave their written, informed consent for participation in the
tudy.
The 3 treatment groups were studied concurrently. Time
ero was defined as the time of initial percutaneous inter-
ention. Patients were treated with 1 of 3 stent types:
ommercially available permanent-polymer RES (Cypher
tent); polymer-free RES (ISAR developed); or commer-
ially available permanent polymer PES (Taxus stent). The
tent platform used in the polymer-free arm consists of a
re-mounted, sand-blasted, 316L stainless steel micro-
orous stent. A detailed description for creating the micro-
ores and its rationale, as well as the specifics of the coating
rocess and the rapamycin solution used, have been reported
reviously (16).
An oral loading dose of 600 mg clopidogrel was admin-
stered to all patients at least 2 h before the intervention,
egardless of whether the patient was taking clopidogrel
efore admission. Immediately after the decision to perform
he intervention, patients were given first, 500 mg aspirin
ntravenously or orally (if they did not receive it within the
rior 12 h), and second, intra-arterial or intravenous heparin
r bivalirudin. Glycoprotein IIb/IIIa inhibitor usage was at
he discretion of the operators. After the intervention, all
atients received 200 mg/day aspirin indefinitely, clopi-
ogrel 150 mg for the first 3 days (or until discharge)
ollowed by 75 mg/day for at least 6 months, and other
ardiac medications according to the judgment of patient’s
hysician (e.g., beta-blockers, angiotensin-converting en-
yme inhibitors, statins).
Rehospitalization for repeat coronary angiography was
cheduled at 6 to 8 months. Patients requiring revascular-
zation of a target lesion at the 6- to 8-month reangiography
ere not considered for further angiographic analysis. The
emaining patients were scheduled for a further follow-up
oronary angiogram at 2 years after the index intervention.
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293linical follow-up was performed by either office visit or
elephone call at 6 to 8 months, 12 months, and 2 years.
ata management, end points, and deﬁnitions. Relevant
ata were collected and entered into a computer database by
pecialized personnel of the Clinical Data Management
entre. Baseline, post-procedural, and follow-up coronary
ngiograms were digitally recorded and assessed offline in
he quantitative angiographic core laboratory (ISAR Centre,
unich, Germany) with an automated edge-detection sys-
em (CMS version 7.1, Medis Medical Imaging Systems,
eiden, the Netherlands) by 2 independent experienced
perators unaware of the treatment allocation. Analysis was
erformed on cineangiograms recorded after the adminis-
ration of intracoronary nitroglycerin using the same single
orst-view projection at all times. The contrast-filled non-
apered catheter tip was used for calibration. Quantitative
nalysis was performed on both the “in-stent” and “in-
egment” area (including the stented segment, as well as
oth 5-mm margins proximal and distal to the stent).
ualitative morphological lesion characteristics were char-
cterized by standard criteria (17).
The primary end point of the study was delayed (or
nterval) in-stent late luminal loss (LLL), defined as the
ifference between the minimal luminal diameter at 6-to-
-month follow-up and the minimal luminal diameter at
-year reangiography, in those patients with paired
ollow-up data. The secondary end points were final 2-year
n-stent LLL for the subgroup with paired angiographic
ollow-up films; composite in-stent LLL for the entire cohort
defined as late loss of all study patients analyzed on the
asis of the latest valid angiographic follow-up whether at 6
o 8 months or 2 years); delayed in-segment binary angio-
raphic restenosis (defined as diameter stenosis 50% in
he in-segment area at 2 years in patients not undergoing
nitial revascularization at 6 to 8 months); and composite
-year in-segment binary angiographic restenosis (defined
s binary restenosis of all study patients analyzed on the
asis of the latest valid angiographic follow-up whether at 6
o 8 months or 2 years). Target lesion revascularization
TLR) was defined as any revascularization procedure in-
olving the target lesion due to luminal renarrowing 50%
n the presence of symptoms or objective signs of ischemia
as determined in advance of angiography).
tatistical analysis. The data is presented as mean  stan-
ard deviation or counts and percentages. Differences be-
ween groups in outcome variables were assessed using the
hi-square test or Fisher exact test (where expected cell
alues were 5) for categorical data. For continuous data,
roups were compared with analysis of variance or Kruskal-
allis rank sum test according to whether the data was
ormally distributed or not. All tests were 2-sided. A p value
f 0.05 was considered statistically significant. Logistic
egression models were established to investigate indepen-
ent predictors of restenosis at 6 to 8 months and at 2 years. phe following clinical variables were entered into the
nalysis model: stent group, age, gender, diabetes, hyper-
ension, hyperlipidemia, cigarette smoker, vessel treated,
omplex lesion morphology, chronic occlusion, ostial lesion,
ifurcational lesion, reference diameter pre-intervention,
esion length, and percentage stenosis of vessel pre-
ntervention.
esults
aseline characteristics and procedural results. The study
atient flow chart is shown in Figure 1. Of 2,588 patients
ndergoing percutaneous intervention in a new coronary
essel, a total of 2,030 patients (78.4%) returned for angio-
raphic follow-up 6 to 8 months after index stenting, had
alid angiographic data, and were therefore considered
ligible for enrollment in this study. Of those not returning
or follow-up, 71 had died (28 [2.4%] in the permanent-
olymer RES group, 13 [2.1%] in the polymer-free RES
roup, and 30 [3.7%] in the permanent-polymer PES
roup; p  0.12). The number of treated lesions was 2,341
1,036 permanent-polymer RES, 565 polymer-free RES,
nd 740 permanent-polymer PES). Baseline clinical char-
cteristics were similar between treatment groups (Table 1).
verall, 28.6% of patients had diabetes mellitus and 74.1%
f lesions had morphology classified as B2/C according to
merican Heart Association/American College of Cardiol-
gy guidelines. The treatment groups were well matched in
erms of lesion and procedural characteristics (Table 2).
ngiographic outcomes at 6 to 8 months. Angiographic
utcomes are summarized in Table 3. The mean time to
nitial scheduled reangiography was 200  85 days. Overall
LL at 6 to 8 months was 0.37  0.56 mm—comprising a
LL of 0.25 0.50 mm, 0.46 0.57 mm, and 0.46 0.59
m for permanent-polymer RES, polymer-free RES, and
ermanent-polymer PES, respectively (p  0.001). Binary
ngiographic restenosis was also significantly different across
he 3 treatment groups: 125 (12.1%), 97 (17.2%), and 127
17.2%) for permanent-polymer RES, polymer-free RES,
nd permanent-polymer PES, respectively (p  0.003).
estricting 6- to 8-month analysis to the subgroup of
esions that subsequently had available 2-year angiographic
ata (n  1,580), LLL for the group was 0.26  0.42
m—0.16  0.37 mm in the patients treated with
ermanent-polymer RES, 0.35  0.46 mm in the polymer-
ree RES stent group, and 0.34  0.44 mm in the
ermanent-polymer PES group (p  0.001).
Target lesion revascularization was required in 259 pa-
ients (12.8%) at the time of 6- to 8-month reangiography
nd accordingly these patients were not considered for
-year angiographic recall (p  0.07 for differences across
roups). Of 1,771 remaining patients (with 2,080 lesions),
alid 2-year angiographic follow-up data, and therefore
aired angiographic follow-up films, were available for
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294,331 (75.2%) patients (with 1,580 [76.0%] treated lesions);
his rate of follow-up was similar across all 3 groups
p  0.58).
ngiographic outcomes at 2 years. Mean time to 2-year
eangiography was 699  239 days; findings are summa-
ized in Tables 3 and 4). With respect to the primary end
Figure 1. Study Design
Patient ﬂow through study. PCI  percutaneous coronary intervention; TLR 
Table 1. Baseline Patient Characteristics
Overall
(n  2,030)
Permanent-Polymer
(n  909)
Age, yrs 65.9 9.8 65.7 10.0
Male 1,858 (79.4) 718 (79.0)
Body mass index, kg/m2 27.2 3.8 27.2 3.9
Diabetes 674 (28.8) 269 (29.6)
Insulin-requiring 203 (10.0) 90 (9.9)
Hypertension 1,553 (66.3) 595 (65.5)
Current smokers 310 (13.2) 124 (13.6)
Hypercholesterolemia 1,770 (75.6) 688 (75.7)
Multivessel disease 1,975 (84.4) 769 (84.6)
Previous myocardial infarction 923 (39.4) 358 (39.4)
Prior bypass surgery 221 (9.4) 88 (9.7)
Ejection fraction,† % 55.5 11.6 55.4 12.1
Lesions/patient 1.19 0.44 1.17 0.43
Plus-minus values are mean SD, otherwise data are shown as n (%). †Data available for 92.4% ofPES paclitaxel-eluting stent; RES rapamycin-eluting stent.oint, overall delayed LLL was 0.12  0.49 mm at 2-year
ngiographic follow-up—0.17  0.50 mm in the cohort
reated with permanent-polymer RES, 0.01  0.42 mm in
he polymer-free RES stent group, and 0.13  0.50 mm in
he permanent-polymer PES group (p  0.001) (Fig. 2).
ith regard to secondary end points, final 2-year LLL in
lesion revascularization.
Polymer-Free RES
(n  494)
Permanent-Polymer PES
(n  627) p Value†
66.7 9.7 65.9 10.0 0.23
391 (79.1) 500 (79.7) 0.94
27.3 4.0 27.1 3.7 0.74
136 (27.5) 176 (28.1) 0.67
51 (10.3) 62 (9.9) 0.94
323 (65.4) 426 (67.9) 0.54
68 (13.8) 84 (13.4) 0.98
361 (73.1) 478 (76.2) 0.43
408 (82.6) 528 (84.2) 0.61
195 (39.5) 254 (40.5) 0.90
45 (9.1) 65 (10.4) 0.78
54.9 11.9 56.0 11.2 0.29
1.20 0.43 1.21 0.46 0.13
s.RES
patient
t
1
p
f
P
o
r
0
m
a
i
[
p
P
a
p
[
m
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 4 , 2 0 0 9
A P R I L 2 0 0 9 : 2 9 1 – 9 9
Byrne et al.
DES and Permanent Polymer
295he group with paired angiographic follow-up lesions (n 
,580) was 0.38  0.56 mm—0.33  0.33 mm for
ermanent-polymer RES, 0.35  0.49 mm for polymer-
ree RES, and 0.47  0.59 mm for permanent-polymer
ES; p  0.001 (Fig. 3).
In terms of composite 2-year LLL, the figure for the
verall group (n  2,341 lesions) was 0.45  0.62 mm—
epresenting 0.37  0.60 mm for permanent-polymer RES,
.47  0.59 mm for polymer-free RES, and 0.55  0.66
m for permanent-polymer PES (p  0.001). There were
Table 2. Lesion and Procedural Characteristics
Overall
(n  2,341)
Permanent-Polyme
(n  1,036)
Ostial 437 (18.7) 197 (19.0)
Bifurcational 625 (26.7) 270 (26.1)
Chronic occlusion 141 (6.0) 64 (6.2)
Complex lesion (type B2/C) 1,735 (74.1) 775 (74.8)
Lesion length, mm 13.7 7.5 14.1 7.8
Reference vessel, mm 2.70 0.50 2.70 0.51
MLD, pre, mm 1.08 0.48 1.07 0.48
Stenosis, pre, % 60.1 15.2 60.6 15.2
Balloon/vessel ratio 1.14 0.11 1.14 0.11
Maximal balloon pressure, atm 14.7 3.0 14.7 3.0
MLD, post, mm 2.58 0.45 2.57 0.45
Stenosis, post, % 8.5 6.3 8.7 6.3
Plus-minus values are mean SD, otherwise data are shown as n (%).
MLDminimal luminal diameter; other abbreviations as in Table 1.
Table 3. Results of 6- to 8-Month and 2-Year Reangiography by Stent Type
Overall Permanent-P
6- to 8-month reangiography
Reangiography interval, days 200 85 203
Lesions analyzed 2,341 1,0
MLD, in-stent, mm 2.21 0.69 2.31
Stenosis, in-stent, % 22.3 20.0 19.1
Late loss, in-stent, mm 0.37 0.56 0.25
MLD, in-segment, mm 1.94 0.65 2.01
Stenosis, in-segment, % 32.0 18.1 30.2
Binary restenosis, in-segment 349 (14.9) 125 (1
2-year reangiography
Reangiography interval, days 699 239 701
Lesions analyzed 1,580 7
MLD, in-stent, mm 2.20 0.67 2.24
Stenosis, in-stent, % 22.5 18.9 21.9
Delayed late loss, in-stent, mm 0.12 0.49 0.17
Composite late loss, in-stent, mm 0.45 0.62 0.37
MLD, in-segment, mm 1.94 0.63 1.95
Stenosis, in-segment, % 32.1 17.3 32.3
Delayed binary restenosis, in-segment 194 (12.2) 92 (1
Composite binary restenosis, in-segment 434 (18.5) 179 (1
Plus-minus values are mean SD, otherwise data are shown as n (%).Abbreviations as in Tables 1 and 2.lso significant differences between the stent groups in the
ncidence of delayed binary angiographic restenosis (92
13.1%] for permanent-polymer RES, 27 [7.2%] for
olymer-free RES, and 75 [15.0%] for permanent-polymer
ES; p  0.002) (Fig. 3) and overall 2-year composite binary
ngiographic restenosis (179 [17.3%] for permanent-
olymer RES, 94 [16.6%] for polymer-free RES, and 161
21.8%] for permanent-polymer PES; p  0.02).
Among 109 lesions with binary restenosis at 6 to 8
onths that did not undergo TLR, 63 were restenosis-free
Polymer-Free RES
(n  565)
Permanent-Polymer PES
(n  740) p Value
96 (17.0) 144 (19.5) 0.49
148 (26.2) 207 (28.0) 0.64
44 (7.8) 33 (4.5) 0.04
415 (73.5) 545 (73.6) 0.79
13.6 6.5 13.4 7.7 0.06
2.70 0.49 2.71 0.51 0.84
1.10 0.46 1.09 0.48 0.15
59.6 14.4 59.7 15.9 0.13
1.14 0.09 1.14 0.11 0.97
14.5 3.0 14.8 2.9 0.36
2.56 0.44 2.61 0.46 0.13
8.3 5.8 8.4 6.56 0.06
r RES Polymer-Free RES Permanent-Polymer PES p Value
197 74 199 88 0.14
565 740
2.09 0.72 2.15 0.72 0.001
24.8 21.4 24.5 20.8 0.001
0.46 0.57 0.46 0.59 0.001
1.86 0.66 1.91 0.67 0.001
33.4 18.9 33.4 18.7 0.001
97 (17.2) 127 (17.2) 0.003
695 237 700 222 0.77
375 501
2.21 0.64 2.15 0.69 0.015
20.5 18.1 24.7 19.8 0.001
0.01 0.42 0.13 0.50 0.001
0.47 0.59 0.55 0.66 0.001
1.96 0.60 1.90 0.65 0.19
29.7 16.4 33.5 18.1 0.004
27 (7.2) 75 (15.0) 0.002
94 (16.6) 161 (21.8) 0.02r RESolyme
88
36
0.65
18.1
0.50
0.63
17.0
2.1)
251
04
0.67
18.6
0.50
0.60
0.63
17.1
3.1)
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296t 2 years. Conversely, of 1,471 nonrestenotic lesions at 6 to
months, 148 met criteria for binary angiographic resteno-
is at 2 years with a significant difference in likelihood of
rogression in favor of those lesions treated with the
olymer-free RES (76 [11.4%] with permanent-polymer
ES, 14 [4.1%] with polymer-free RES, and 58 [12.6%]
ith permanent-polymer PES; p  0.001).
ultivariate analysis. Predictors of LLL at 6- to 8-month
eangiography were stent group (favoring permanent-
olymer RES), patient age, complex lesion morphology,
hronic occlusion, ostial lesion location, and lesion length.
nly stent type (in favor of polymer-free RES) remained a
redictor of delayed LLL between 6 to 8 months and 2 years
Table 5). In terms of binary angiographic restenosis, stent
roup (favoring permanent-polymer RES), hypertension,
omplex lesion morphology, chronic occlusion, and pre-
rocedure reference diameter predicted 6- to 8-month
estenosis while stent type (in favor of polymer-free RES),
iabetes, chronic occlusion, ostial lesion location, and pre-
rocedure reference diameter predicted later delayed
estenosis.
linical outcomes. During the 6 to 8 months following
ndex percutaneous coronary intervention, 259 patients
Table 4. Overall Results of 6- to 8-Month and 2-Year Reangiography
Pre-Procedure
Lesions with 6- to 8-month follow-up (n  2,341)
MLD, in-stent, mm 1.07 0.48
Late loss, in-stent, mm
Lesions with 2-year follow-up (n  1,580)
MLD, in-stent, mm 1.09 0.47
Late loss, in-stent, mm
Plus-minus values are mean SD.
Abbreviations as in Table 2.
Figure 2. Primary End Point: LLL
Data are displayed as mean  standard error of mean. LLL  late luminal
loss; PES  paclitaxel-eluting stent; RES  rapamycin-eluting stent.12.8%) underwent TLR (99 [10.9%] in the permanent-
olymer RES group, 73 [14.8%] in the polymer-free RES
roup, and 87 [13.9%] in the permanent-polymer PES
roup; p  0.07). At 2 years, TLR had been performed in
08 (20.1%) patients (171 [18.8%], 86 [17.4%], and 151
24.1%] in permanent-polymer RES, polymer-free RES,
nd permanent polymer PES groups, respectively; p 
.009).
At 2-year follow-up, 77 of 2,030 enrolled patients had
ied (3.8%). Differences in 2-year mortality across the
reatment groups were of borderline significance (30 [3.3%],
4 [2.8%], and 33 [5.3%] in permanent-polymer RES,
olymer-free RES, and permanent-polymer PES groups,
espectively; p  0.06).
iscussion
n this large-scale, 2-center prospective systematic angio-
raphic follow-up study, we found that ongoing reduction
n luminal caliber beyond 6 to 8 months after index stenting
Post-Procedure 6 to 8 Months 2 Years
2.57 0.45 2.21 0.69
0.37 0.56
2.58 0.46 2.32 0.58 2.20 0.67
0.26 0.42 0.38 0.62
Figure 3. Secondary End Point: Binary Angiographic Restenosis
Shaded bars represent restenosis at 6 to 8 months. Full-color bars repre-
sent delayed (interval) restenosis at 2 years in patients who did not
undergo revascularization at 6 to 8 months. pinterval represents p value for
differences in interval progression between 6 to 8 months and 2 years.
Abbreviations as in Figure 2.
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297rocedure is a feature of DES therapy and that there appears
o exist a device specificity in this delayed attenuation of
ntirestenotic efficacy in favor of a platform devoid of
ermanent polymer. These findings lend support to the
ypothesis of a possible late “catch-up” restenosis, predi-
ated to a large extent on observations in earlier animal
odels and anecdotal clinical experience (5–7,9,10,18,19).
n those patients with paired 6- to 8-month and 2-year
ngiographic follow-up results, overall 2-year LLL was 0.38
0.56 mm. This comprised a delayed LLL of 0.12  0.49
m over and above 0.26  0.42 mm observed at initial
eangiography. These observations are in marked contrast to
ndings from studies with late angiographic follow-up in
he era of BMS, which revealed a peak in BMS restenosis at
months in human subjects (13–15). Thereafter, volumes
f restenotic plaque tend to remain stable or indeed regress,
t least over the medium term (up to 4 years) (20), most
ikely due to completion of vessel wall healing in association
ith a degree of positive remodeling, and consequently a
tabilization or modest increase in luminal caliber. As
estenosis tended to have “declared itself” at 6 to 9 months
fter intervention, this time window was historically con-
idered appropriate for angiographic restudy and continued
o be thought of as such into the era of DES.
Intuitively, the time course of restenosis in the DES era
ight be considered quite different. In addition to the
ndings from animal studies, numerous reports in DES-
reated human subjects have documented ongoing vessel
all inflammation and failure of re-endothelialization in
ubjects in excess of 12 months after coronary stenting
9,21–24). A very convincing body of experimental and
linical evidence implicates such inflammation as the pri-
ary driver of restenosis via the vehicle of neointimal
yperplasia (25). As intravascular ultrasonic follow-up was
eyond the scope of this current analysis, we are unable to
onfirm that the observed “late luminal creep” is definitively
ue to neointimal hyperplasia, although any other mecha-
ism seems highly unlikely. The prime suspect for this
ersistent inflammatory response in DES-treated patients
Table 5. Multivariate Predictors of LLL at 6- to 8-Month
and 2-Year Reangiography
Late Loss at 6 to 8 Months Late Loss at 2 Years
Stent group 0.001* 0.001†
Age 0.001
Diabetes 0.05
Complex lesion (B2/C) 0.001
Chronic occlusion 0.001
Ostial lesion 0.001
Lesion length 0.001
*Permanent-polymer RES stent superior. †Polymer-free RES stent superior.
LLL late luminal loss; other abbreviations as in Table 1.eems to be residual permanent polymer that results in Lersisting proinflammatory and thrombogenic effects and
ay present a spectrum of clinical syndromes, ranging from
ystemic hypersensitivity reactions, through late stent
hrombosis and late malapposition, to late-onset in-stent
estenosis. In addition, failure of stent endothelialization in
tself clearly presents a nidus for platelet activation and fibrin
eposition, which may initiate the chemokine cascade
eading to neointimal hyperplasia, quite independent of the
resence of permanent polymer.
To date, the magnitude of the problem due to late
eointimal growth consequent on ongoing vessel wall in-
ammation remains largely unstudied. Clinical and patho-
ogical case reports and adverse event series are by their
ature anecdotal. Few studies have reported long-term
nvasive follow-up in DES-treated patients in a systematic
ashion. What limited data exists is typically based on
xtended follow-up of patients treated with DES implan-
ation early in the DES era and involves relatively simple
esion subsets. Aoki et al. (26) reported the results of 2-year
ntravascular ultrasound analysis in 161 patients treated with
low- or moderate-release permanent-polymer PES or with
MS. They found that whereas BMS-treated patients
howed a compaction of the neointima between 6 months
nd 2 years, the DES-treated groups exhibited an increase
n neointimal volume albeit without evidence of a loss of
uminal caliber. Park et al. (27) reported 2-year invasive
ollow-up on 53 patients treated with an experimental
olymer-free PES and surprisingly noted a catch-up phe-
omenon restricted to a subgroup treated with a higher-
ose-PES. Even though Sousa et al. (28) report angio-
raphic follow-up as far out as 4 years after implantation of
arly model RES, their results similarly lack general appli-
ability due to the low number of patients studied (n  30)
nd the inclusion of only simple coronary lesions.
Although reports of a maintained clinical superiority of
ES over BMS out to 4 years (as far as TLR is concerned)
re reassuring (29–32), the implications of our data may
ave particular relevance as regards the conduct of future
rials comparing different stent platforms and the choice of
he most appropriate time point for protocol-mandated
ngiographic follow-up. As concerns regarding increasingly
arge sample sizes (in superiority comparison trials) and
fficacy drift (in studies with a noninferiority design) come
o the fore, there is an accumulating evidence base on the
alidity of angiographic surrogates of clinical device efficacy
n DES trials (33–36). Furthermore, the influence of
rotocol-mandated follow-up reangiography on rates of
LR has also prompted the suggestion that protocol an-
iography be standardized at 13 months after index percu-
aneous coronary intervention—a time point beyond that of
rimary 12-month clinical end point assessment (37). How-
ver, as the time point at which restenotic plaque volume in
ES might be expected to peak remains unknown and as
LL and binary restenosis appear to be dynamic ongoing
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298rocesses between 6 to 8 months and 2 years, perhaps
aution is necessary in the interpretation of interdevice
fficacy comparisons based solely on angiographic follow-up
t this proposed time point.
Importantly, we observed that interval LLL in this
urrent analysis was a phenomenon restricted only to
ermanent-polymer-based stents—no appreciable interval
oss was seen with the polymer-free RES platform. In actual
act, a multivariate analysis model showed that the only
redictor of interval LLL was stent type (in favor of the
olymer-free RES platform). Although differences between
ES platform performances may be due to any of its
rimary components—namely stent backbone, active drug,
r type of polymer—absence of permanent polymer is the
istinguishing feature of the polymer-free RES in this
urrent comparison. These observed differences in interval
LL may represent the first evidence that the absence of
ermanent polymer from the coronary milieu over the mid-
o long-term may translate into an improved late antirest-
notic efficacy, in addition to the attractive proposition of an
nhanced safety profile in the context of the risk of late stent
hrombosis. In this regard, though we previously demon-
trated superior and equivalent efficacy of the polymer-free
ES platform against BMS (16) and Taxus (38), respec-
ively, the limitations of the drug release kinetics inherent to
platform devoid of drug polymer resulted in an antirest-
notic efficacy inferior to that of the Cypher stent, when this
as used as comparator (39). Encouraging clinical results
ith novel DES using biodegradable polymers have been
ublished recently. These platforms show equivalent angio-
raphic and clinical outcomes to Cypher at 9 to 12 months,
nd as they theoretically become equivalent to a polymer-
ree platform at 6 to 8 weeks, the potential of maintained
ow levels of LLL out to 2 years is an interesting prospect
39,40).
tudy limitations. This study was designed to assess changes
n antirestenotic efficacy of DES over a 2-year time period
ollowing stent implantation. Inherent in the analysis of our
rimary end point was the exclusion of patients requiring
evascularization at initial 6- to 8-month follow-up as at this
oint, time zero was considered to be reset. The influence of
urvival bias is unavoidable. Questions pertaining to clinical
utcomes or device safety (including late stent thrombosis)
re not specifically addressed in this paper. Intergroup
omparison between cohorts treated with different stent
latforms are limited by the nonrandomized nature of our
nvestigation. Among patients with restenosis who did not
ndergo TLR and were subsequently restenosis-free at 2
ears, while neointimal contraction is 1 possible explana-
ion, the margin of error associated with quantitative coro-
ary angiography analysis may also have contributed.
The choice of any specific time point after the index
tenting procedure as the point for late reangiography may
e regarded as somewhat arbitrary given the lack of evidences to when restenotic plaque volume may be expected to
eak. Although we acknowledge that direct imaging of the
oronary vessel wall may strengthen the assertion that
ngoing reduction in luminal caliber is definitively due to
eointimal hyperplasia, any other mechanism seems highly
nlikely.
onclusions
e have demonstrated that ongoing LLL beyond 6 to 8
onths after the index procedure is observed following
ES implantation. Absence of permanent polymer from
he DES platform seems to militate against this late
eduction in antirestenotic efficacy. These findings may have
mplications regarding the time point of efficacy assessment
n future DES trials and the role of permanent polymer in
uture DES designs.
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